Autopsy report · NCT02072057

Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

“Poor recruiting”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 years 7 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Kantonsspital Aarau

Sponsor type

University, hospital or other

Conditions

Cancer Cachexia

Interventions

Ruxolitinib

Participants

8

Sites

2

Countries

Switzerland

Trials that died the same way

• Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy
  “recruiting inadequate” (88% match in meaning)
• Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin Secretion
  “poor recruitment” (83% match in meaning)
• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (82% match in meaning)
• Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery
  “not enough recruits” (77% match in meaning)
• Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease
  “poor recruitment status” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.